RxDoctor Payments Data

Jackylin Caparas, MD

Internal Medicine · Fort Wayne, INNPI 1881991834

Payments from drug & device makers

$261in general payments, 2019–2025

Across 9 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$109
  • Lilly USA, LLC$41
  • Pfizer$21
  • Novo Nordisk$21
  • Lundbeck LLC$19
  • AbbVie$19
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$261 in reported general payments places this provider in the 55th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$85,360
Medicare patients
245
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$94,731
JardianceEmpagliflozin54$82,591
TrulicityDulaglutide35$61,411
MounjaroTirzepatide42$56,643
EliquisApixaban35$48,301
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$40,436
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$38,525
JanuviaSitagliptin Phosphate19$29,949
XareltoRivaroxaban17$23,696
TopamaxTopiramate12$16,153
Tresiba Flextouch U-100Insulin Degludec14$12,757
Spiriva RespimatTiotropium Bromide13$9,906
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$9,689
Novolog FlexpenInsulin Aspart12$5,507
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$41$118,05477 claims
Novo NordiskOzempic$21$94,73166 claims
PfizerEliquis$21$48,30135 claims
Johnson & JohnsonXarelto$109$23,69617 claims
AbbVieSynthroid$19$4,32268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →